Hemcheck Sweden AB: Presents results from user tests at Karlstad Central Hospital
21 June 2017 - 5:00PM
Hemcheck Sweden AB (publ)
presents results from user tests at Karlstad Central
Hospital
hemCheck, a medical technology
company addressing the issue of hemolysis, announces results from
user tests at Karlstad Central Hospital, where nurses used a
prototype of hemCheck's point of care test in a clinical setting.
The user tests confirmed that hemolysis is a significant problem
for the emergency department, showed that the prototype is user
friendly and that the rate of hemolysis for Troponin T tests could
be lowered by 75% when using this prototype.
hemCheck carried out user tests of a prototype of
its point of care hemolysis detection test, Helge, in the emergency
department at Karlstad Central Hospital during December 2016 to May
2017. The purpose of the trial was to gain a better understanding
of user friendliness and test performance in a clinical setting, in
order to identify improvement areas for the upgraded product
version, including a digital reader, which is being developed for
evaluation and testing.
The measured rate of hemolysis in the ER-setting
was on average 10.2% for all the blood samples in the control
group, strengthening our view on the extent of the issue. The rate
was significantly higher (21%) when using peripheral venous
catheters (PVCs) and when a slow blood flow was observed (36%).
Hemolysis rates varied highly (3 to 19%) among nurse participants,
and nurses could correctly predict hemolysis in less than one third
of all cases.
The Helge prototype was considered user friendly
and was easily incorporated in the clinical setting. Using the
current prototype (set for hemolysis index (HI) cutoff 50), lowered
the hemolysis rate for Troponin T tests (HI cutoff 100) by 75%, and
the hemolysis rate for Potassium, ALAT, ALP tests by 36% (HI cutoff
50). Adjustments to the prototype, including the use of a digital
reader, are being made to improve performance accuracy for
hemolysis sensitive analyses, such as Potassium, ALAT, ALP.
hemCheck CEO Annelie Brolinson
comments:
- These user tests have clearly confirmed the relevance of
hemolysis and align well with published clinical findings. With a
prototype in the development phase, we are very proud to receive
such a positive response among users, and that indicates that we
are on the right track with our unique point of care test. With
this knowledge, we now continue our work of enhancing the product
concept's ability to identify hemolyzed blood samples, thereby
improving patient safety and patient flows within the health care
system.
About hemCheck
hemCheck Sweden AB (publ) is developing and commercializing a
unique product concept, Helge, that detects hemolysis in blood
samples at the point of care. Hemolysis, or the rupturing of red
blood cells, is the most common reason for blood samples being
ruled unfit for analysis. This can lead to lower quality
healthcare, increased risks for patients and higher costs. By
instantly detecting hemolysis in blood tests, Helge can contribute
to improved care for patients throughout the world. hemCheck is
headquartered in Karlstad, Sweden.
Contact
hemCheck Sweden AB (publ)
Annelie Brolinson, CEO
Tel: +46 70 288 0826
E-post: annelie.brolinson@hemcheck.com
Universitetsgatan 2
651 88 Karlstad
www.hemcheck.com
Important information
This is information which hemCheck is required to disclose
according to EU Market Abuse Regulation law. The information was
provided by the above contact person's auspices, for publication on
June 21, 2017, at 09:00.
Press release
20170621_eng
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Hemcheck Sweden AB via Globenewswire
Hsbc Msci Em Ac (LSE:HEMC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Hsbc Msci Em Ac (LSE:HEMC)
Historical Stock Chart
From Nov 2023 to Nov 2024
